Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 45-48

  Rustin, G J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

CA125; Follow up; Ovarian cancer; Relapse; Tumour progression

Indexed keywords

CA 125 ANTIGEN; PLATINUM; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADVANCED CANCER; ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT INDICATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; NEOPLASM; OVARIAN EPITHELIAL CANCER; OVARY TUMOR; PATHOLOGY; SURVIVAL; TIME; TREATMENT OUTCOME; WATCHFUL WAITING;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84857405045     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr471     Document Type: Conference Paper

References (11)

1. Oskay-Oezcelik G, du Bois A, Fasching PA et al. What do patients think about CA-125 monitoring in the follow-up? Results form a multi-center trial in 1060 patients with ovarian cancer. J Clin Oncol 2009; 27 (Suppl 15): Abstract 5522.
2. Rustin GJ. What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer? Int J Gynecol Cancer 2010; 20 (Suppl 2): S27-28.
3. Rustin GJS, van der Burg MEL, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.
4. Goto T, Takano M, Watanabe A et al. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Gynecol Cancer 2011; 21: 263-268.
5. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006; 13: 1702-1710.
6. Hurteau JA, Brady MF, Darcy KM et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group study. Gynecol Oncol 2010; 119: 444-450.
7. Burger R, Brady M, Bookman M et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010; 28 (18s): (LBA1).
8. Perren T, Swart AM, Pfisterer J et al. ICON 7: a phase III randomised Gynecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010; 21: VIII2.
9. Schwartz PE. Fifth Alon Dembo Memorial Workshop: case 3. Int J Gynecol Cancer 2010; 21: (Suppl 8), (LBA4) viii 2.
10. Morris RT, Monk BJ. Ovarian cancer: relevant therapy, not timing, is paramount. Lancet 2010; 376: 1120-1122.
11. Rustin G, van der Burg M, Griffin C et al. Early versus delayed treatment of relapsed ovarian cancer. Lancet 2011; 377: 380-381.